Verseau is focused on developing the next major wave of cancer immunotherapies directed at a broad and potent reprogramming of the tumor microenvironment to attack tumors. 

Biotechnology

Verseau Therapeutics

Susan Low

Karen Tubridy

Lou Vaickus

Tatiana Novobrantseva

The executive team at Verseau Therapeutics has a history in computational biology and working for companies such as Epizyme, Jounce Therapeutics, and Merck. They also have a strong educational foundation, with degrees from Columbia University in the City of New York in Biology and Computational Biology.

CEO and Executive Team

About

Team members

Other teams at Verseau Therapeutics

Board of Directors

Leadership Team